KRTX News and Press, Karuna Therapeutics Inc. From 03/07/24

2024-03-07 14:32:17 ET Summary Bristol-Myers Squibb might have seen a price decline over the past year, but it now boasts of a superior dividend yield and competitive P/E ratio compared to peers. After a revenue setback on the patent erosion of its cancer treatment drug, it's now ...

2024-02-23 15:00:00 ET More on the markets SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat SPY: The U.S. Is Positioned To Expand Its Global Dominance S&P 500: Correction In Progress, Deeper Selloff Expec...

2024-02-21 07:15:00 ET Summary We have been short Karuna Therapeutics (KRTX) for most of 2023. Karuna are developing a drug (which they have coined "KarXT") for the treatment of schizophrenia. Bristol-Myers Squibb, a major global pharmaceutical company, has just bid 14 billion...

2024-02-21 06:05:00 ET Summary Bronte Capital is an Australian-licensed and USA SEC-registered Global Fund Manager and focuses on generating alpha from both its long and short portfolio in a unique, uncorrelated and sustainable manner. Amalthea lost -2.12% in December, -0.97% for ...

2024-02-18 10:22:04 ET Summary Karuna Therapeutics is developing a novel product, KarXT, to treat psychoses related to Alzheimer's and schizophrenia. The product targets muscarinic receptors in an agonist/antagonist combination. Some shareholders are suing to prevent the acqui...

2024-02-18 08:45:38 ET Summary Top 10 merger arb stocks held by funds include Splunk and Pioneer Natural Resources Company. Two of the top four deals are oil related. This quarter funds have oversized positions in certain stocks. Each quarter, I compile the top 10 st...

2024-02-17 01:00:00 ET Summary Since October 27th (less than four months ago), the S&P 500 ETF (SPY) is now up 22.8%. That's a big move. The Tech-heavy Nasdaq 100 (QQQ) is up even more at 25.95%, and interestingly, the small-cap Russell 2,000 (IWM) is up nearly the same amount...

2024-02-10 19:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-06 08:19:58 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: All Focus On Execution Bristol-Myers Squibb: Massive Discount Spells Opportunity Bristol-Myers Squibb Company 2023 Q4 - Results - Earnings Call Presentation Bristol Myers, 2seventy bio ...

2024-02-05 04:01:47 ET Summary Bristol-Myers Squibb is pursuing aggressive M&A to address its growth challenges and loss of exclusivity for its top-selling drug Revlimid, ahead of more expirations due. The company's net debt load is substantial, and it relies heavily on a few ...